Literature DB >> 24976388

Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.

Antonio Piga1, Filomena Longo, Raffaella Origa, Simona Roggero, Francesca Pinna, Antonietta Zappu, Chiara Castiglioni, Maria Domenica Cappellini.   

Abstract

Entities:  

Keywords:  heart; iron chelation; iron overload; magnetic resonance imaging

Mesh：

Substances：

Year:  2014        PMID： 24976388     DOI： 10.1111/bjh.12987

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  A USPIO doped gel phantom for R2* relaxometry.

Authors:  Gregory C Brown; Gary J Cowin; Graham J Galloway
Journal:  MAGMA       Date:  2016-07-19       Impact factor: 2.310

2.  Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.

Authors:  Sefika Pinar Senol; Eyup Naci Tiftik; Selma Unal; Aydan Akdeniz; Bahar Tasdelen; Bahar Tunctan
Journal:  J Basic Clin Pharm       Date:  2016-03

3.  Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.

Authors:  Osama Tanous; Yossi Azulay; Raphael Halevy; Tal Dujovny; Neta Swartz; Raul Colodner; Ariel Koren; Carina Levin
Journal:  BMC Nephrol       Date:  2021-12-20       Impact factor: 2.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.